Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 9/20 | 0.41 |
| ▸ | MAOA | P21397 | 7/20 | 0.41 |
| ▸ | KDM1A | O60341 | 5/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101268 | 1.00 | TSHR (0.43) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL15564897 | 1.00 | TSHR (0.43) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL4101267 | 1.00 | TSHR (0.43) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL15564899 | 1.00 | TSHR (0.43) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL12519603 | 0.84 | TSHR (0.44) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL11421880 | 0.84 | TSHR (0.52) | TSHRMAOBMAOAKDM1ACYP2C19 | |
| SCHEMBL20408740 | 0.79 | HTR2A (0.39) | HTR2CTAAR1SLC6A2SLC6A3SLC18A3 | |
| SCHEMBL3168114 | 0.79 | KDM1A (0.45) | KDM1AHTR2CSLC6A2SLC6A3HTR2B | |
| SCHEMBL3174322 | 0.79 | KDM1A (0.45) | KDM1AHTR2CSLC6A2SLC6A3HTR2B | |
| SCHEMBL18264216 | 0.79 | HTR2A (0.39) | HTR2CTAAR1SLC6A2SLC6A3SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108368057-B | Pyrazolo-fused heterocyclic compounds as ERK inhibitors | 捷思英达医药技术（上海）有限公司 | 2022-03-15 | — | — | CN | disclosed |
| EP-3337787-B1 | 1H-PYRAZOLO[3,4-B]PYRIDINE, 1H-THIENO[2,3-C]PYRAZOLE AND 1H-INDAZOLE CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS EXTRACELLULAR SIGNAL-REGULATED KINASES (ERK) INHIBITORS FOR TREATING CANCER | JS INNOPHARM SHANGHAI LTD (CN) | 2021-03-03 | — | — | EP | disclosed |
| US-10696687-B2 | Pyrazolo fused heterocyclic compounds as ERK inhibitors | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-20180237450-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2018-08-23 | — | — | US | disclosed |
| EP-3337787-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | Changzhou Jiekai Pharmatech Co. Ltd. (CN) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017028314-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017028314-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | CHANGZHOU JIEKAI PHARMATECH CO., LTD. (CN) | 2017-02-23 | — | — | WO | disclosed |
| US-9271967-B2 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2016-03-01 | — | — | US | disclosed |
| EP-2649069-B1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2015-08-26 | — | — | EP | disclosed |
| US-20130338185-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2649069-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012062750-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | Janssen Pharmaceuticals, Inc. (US) | 2012-05-18 | — | — | WO | disclosed |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-1981865-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007090840-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237450-A1 | PYRAZOLO FUSED HETEROCYCLIC COMPOUNDS AS ERK INHIBITORS | MAPK1, MAPK3, MAP3K20 | TSHR 2863/4885MAOB 3799/4885MAOA 3884/4885 |
| US-20090221643-A1 | 4-PHENYL-3-(2-PROPYLSULFONYLAMINO) TETRAHYDROFURAN DERIVATIVES WHICH POTENTIATE GLUTAMATE RECEPTORS AND ARE USEFUL IN THE TREATMENT OF SCHIZOPHRENIA | GRIN2C, GRIN1, OXER1 | TSHR 524/4885MAOB 2741/4885MAOA 3021/4885 |
| US-20130338185-A1 | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRM3 | TSHR 370/4885MAOB 2609/4885MAOA 2416/4885 |
| US-10696687-B2 | Pyrazolo fused heterocyclic compounds as ERK inhibitors | MAPK1, MAPK3, MAP3K20 | TSHR 2863/4885MAOB 3799/4885MAOA 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.